Display Settings:

Format

Send to:

Choose Destination
    Clin Gastroenterol Hepatol. 2008 Feb;6(2):255-8. Epub 2008 Jan 9.

    Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases.

    Source

    Department of Gastroenterology, Lahey Clinic Medical Center, Burlington, Massachusetts 01805, USA.

    Abstract

    BACKGROUND & AIMS:

    Methasteron is a nutritional supplement used to increase weight or accelerate the build-up of muscle mass. The aim of this study was to describe 5 cases of hepatotoxicity in patients using methasteron seen at tertiary-care medical centers.

    METHODS:

    A case report design was used.

    RESULTS:

    Five previously healthy patients who used methasteron developed jaundice 2 weeks after discontinuation; they presented to a tertiary-care medical center 2 weeks later. Within another 2 to 3 weeks, bilirubin levels peaked. About 12 weeks after initial presentation, all cases resolved with no identifiable residual hepatic dysfunction.

    CONCLUSIONS:

    Methasteron use can result in severe hepatotoxicity. Liver failure can worsen after initial presentation, especially within 2 weeks. With close observation and supportive care, acute hepatic injury should resolve.

    PMID:
    18187367
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk